wAMD
Ahzantive
wAMD
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
mCNV
Ahzantive
mCNV
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
CRVO
Ahzantive
CRVO
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
BRVO
Ahzantive
BRVO
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
DMO
Ahzantive
DMO
Welcome to your aflibercept guide!
This booklet has been produced for people who have been prescribed
aflibercept (aflibercept solution for injection) for the treatment of diabetic
macular oedema, or DMO.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Suspected adverse reactions should be reported to the MHRA via Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Summary of important safety information
Contact your doctor as soon as possible if you experience any of the following symptoms after treatment with Aflibercept:
- If any eye pain or redness following the injection does not go away or is getting worse
- If your vision gets more blurred or you can’t see as well as usual
- If you become more sensitive to light
- If you experience the sudden appearance of floaters, flashes of light and/or obscured vision
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report suspected side effects to the MHRA through the Yellow Card scheme. You can report via:
- the Yellow Card website www.mhra.gov.uk/yellowcard
- the free Yellow Card app available from the Apple App Store or Google Play Store
Alternatively you can report a side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible.
Please ensure that you provide the brand name (or product licence number and manufacturer), and the specific batch-number.
By reporting side effects, you can help provide more information on the safety of this medicine.
Welcome to your Aflibercept guide
This booklet has been produced for people who have been prescribed Aflibercept (aflibercept solution for injection) for the treatment of diabetic macular oedema, or DMO.
The booklet is available as a digital version and comes with an audio guide. The audio guide is a readout of the text in this patient booklet. This information can be accessed by using the camera on a smart device to scan the relevant QR codes. This will direct the device to relevant information on the internet.
Please use the QR-Code or web address to access the audio format or to download this guide:
https://medinfo.formycon.com/ahzantive/uk/en
More information is available to you in the Patient Information Leaflet (PIL). Your doctor has prescribed Aflibercept because you have been diagnosed with DMO.
What is DMO?
Diabetic macular oedema (DMO) is a condition that occurs when fluid builds up in the retina. The retina is the layer of cells lining the back wall inside your eye. It senses light and lets you see by sending messages to the brain. The macula is an important area at the centre of the retina that allows you to see clear details of objects in front of you, like faces and words in books.
Diabetes can cause high or rapidly changing blood sugar levels. This can result in damage to small blood vessels around the body, and if this happens in the eye it may lead to swelling in the retina and blurry vision (DMO). The swelling is due mainly to higher than normal levels in the eye of a protein called VEGF. VEGF occurs naturally in the body and is involved in making blood vessels grow, but too much VEGF in the retina can trigger the growth of abnormal, leaky blood vessels. When vessels in the eye leak blood or other fluids this causes swelling of the retina. Over time without treatment, this process can lead to scarring in the macula and permanent central vision loss.
What is Aflibercept?
Aflibercept is a type of treatment known as an anti-VEGF. Anti-VEGF is an abbreviation for anti-vascular endothelial growth factor, and this is andescription of how Aflibercept works to protect your vision. Aflibercept blocks VEGF, and this action helps reduce the swelling in the retina and can lead to vision improvement and maintenance of your vision. Aflibercept is a solution (a liquid) that is injected into the eye.
This medicine is available in a 2 mg dose. Your doctor will recommend a treatment schedule for you and it is very important that you follow it.
Who is Aflibercept for?
Aflibercept is for people who have been diagnosed with DMO.
What should your doctor know before you are treated with Aflibercept?
Before your Aflibercept treatment starts, make sure to tell your doctor or healthcare providers if you:
- Have an infection in or around your eye
- Currently have redness in your eye or if there is any pain in your eye
- Think you may be allergic to iodine, any painkillers or any of the ingredients in this medicine. The full list of ingredients can be found in the attached Package Leaflet
- Have had any issues or problems with eye injections before
- Have glaucoma or a history of high pressure in your eye
- See, or have seen, flashes of light or ‘floaters’ in your vision
- Are taking any medications, with or without a prescription
- Had or will have eye surgery within 4 weeks before or after Aflibercept treatment
- Are pregnant, planning to become pregnant or breastfeeding.
There is very little information about the safety of using Aflibercept in pregnant women. Aflibercept 2 mg should not be used during pregnancy, unless the benefit outweighs the risk to the baby. Discuss this with your doctor before treatment with Aflibercept.
Women of childbearing potential should use effective contraception during their treatment and for at least 3 months after the last injection of Aflibercept. Use of Aflibercept is not recommended during breastfeeding as small amounts of Aflibercept may enter into the breastmilk, and its effects on a newborn/infant are not known.
How can I get ready for my Aflibercept appointment?
Your doctor may ask you to take eye drops for a few days before your appointment. After your treatment, your vision may be blurry so you should not drive home. Plan to have a friend or family member to take you to your appointment, or arrange another way to get there and home again. On the day of your appointment, do not wear any makeup.
What can I expect after my Aflibercept appointment?
Your doctor may give you some eye tests after your Aflibercept injection. This may include a test that measures the pressure inside your eye. After your injection, your vision may be blurry, so you should not plan to drive until your vision returns to what is normal for you.
If you use contact lenses, your doctor or nurse can advise you when you can start using them again.
Over the next few days you may get a bloodshot eye or see moving spots in your vision. Both of these should improve within days. If they don’t, or if they get worse, you should contact your doctor.
Some people might feel a little bit of pain or discomfort in their eye after their injection. If the pain does not go away or gets worse, you should contact your doctor.
Does Aflibercept have side effects?
Just like any medicine, Aflibercept has the potential to cause side effects. Not everyone who is given an Aflibercept injection will experience a side effect.
Contact your doctor immediately if you have any signs or symptoms listed in the table below as these could be signs of a serious complication with the treatment:
Condition
Some potential signs or symptoms
Infection or inflammation inside the eye
- Eye pain or increased discomfort
- Worsening eye redness
- Sensitivity to light
- Swelling of the eyelid
- Vision changes such as sudden decrease in vision or blurring of vision
Clouding of the lens
(cataract)
- Blurry vision
- Seeing shadows
- Less vivid lines and shapes
- Colour vision changes (e.g. colours looked ‘washed out’)
Increase in pressure
in the eye
- Seeing halos around lights
- Eye pain
- Experiencing a red eye
- Nausea or vomiting
- Vision changes
A detachment or tear of a layer of the retina
- Sudden flashes of light
- A sudden appearance or an increase of floaters
- A curtain-like effect over a portion of the visual area
- Vision changes
For a full list of side effects, please refer to the Aflibercept Patient Information Leaflet (PIL). You can access the PIL using the QR code at the beginning of this booklet, or by asking your doctor.
What if I have concerns or questions?
If you have any concerns or questions, your doctor or nurse is the best person to speak to. They are very experienced and they know your individual situation so can provide you with the answers you need.
Your eye care clinic is:
Contact:
Telephone:
Address:
Email:
Where can I find out more about DMO?
If you would like to find out more, or be put in touch with other people suffering from DMO, a list of useful contacts can be found below. You can write to these organisations, phone them or, if you have access to the internet, go to their websites. These organisations will have downloadable files of information which can be printed or read on the screen. They may also be able to provide their information in audio format for you to listen to.
The Macular Society
Helpline: 0300 3030 111
Address: The Macular Society, PO Box 1870, Andover SP10 9AD
Email: info@macularsociety.org
Website: www.macularsociety.org
RNIB (Royal National Institute of Blind People)
Helpline: 0303 123 9999
Address: Grimaldi Building, 154a Pentonville Road, London N1 9JE
Email: helpline@rnib.org.uk
Website: www.rnib.org.uk
EN
Ahzantive
Information about Ahzantive® for Patients and Healthcare Professionals
Ahzantive® (aflibercept)
Package leaflet: Information for the adult patient
Information for the adult patient
Ahzantive®
40 mg/ml
solution for
injection in
a vial
Information for the adult patient
Ahzantive®
40 mg/ml solution for injection in pre-filled syringe
Ahzantive® (aflibercept)
Summary of Product Characteristics
Summary of Product Characteristics –
Information for Health Care Professionals
Ahzantive®
40 mg/ml
solution for
injection in
a vial
Summary of Product Characteristics –
Information for Health Care Professionals
Ahzantive®
40 mg/ml solution for injection in pre-filled syringe
Patient booklet –
your guide to Ahzantive® (aflibercept)
Prescriber Guide to intravitreal injections with Ahzantive® (aflibercept)
Prescriber Guide
Ahzantive®
40 mg/ml solution for injection in a vial and
40 mg/ml solution for injection in pre-filled syringe
Reporting of side effects
If you notice any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk
Please ensure that you provide the brand name, and the specific batch-number.
By reporting side effects you can help provide more information on the safety of this medicine.
Alternatively you may report side effects by email to:
medinfo@formycon.com
The data processing is in accordance with the legal requirements. Further information can be found here.
UK
Ahzanive
Informatie over Ahzantive® voor patiënten en professionals in de gezondheidszorg
Risico minimalisatie materiaal betreffende informatie over Ahzantive® voor patiënten
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
DME
(diabetisch
maculaoedeem)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
LMD
(neovasculaire (natte) leeftijdsgebonden maculadegeneratie)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
mCNV
(myope choroïdale neovascularisatie)
Risico minimalisatie materiaal betreffende informatie over Ahzantive® (aflibercept) voor patiënten:
RVO
(retinale veneuze
occlusie)
Risicominimalisatie-materiaal over de risico’s van aflibercept voor voorschrijvers en video over de intravitreale injectieprocedure
Risicominimalisatie-
materiaal over de risico’s
van aflibercept voor
voorschrijvers
Ahzantive®
40 mg/ml oplossing voor injectie in een injectieflacon
Video over de intravitreale injectieprocedure voor beroepsbeoefenaren in de gezondheidszorg
Ahzantive®
40 mg/ml oplossing voor injectie in een injectieflacon
Bijwerkingen
Neem contact op met uw arts, apotheker of verpleegkundigen als u last krijgt van bijwerkingen. Dat geldt ook voor mogelijke bijwerkingen die niet in de bijsluiter staan.
Door deze bijwerkingen te melden kunt u helpen meer informatie te geven over de veiligheid van dit medicijn.
U kunt bijwerkingen melden via het Nederlands Bijwerkingencentrum Lareb.
U kunt bijwerkingen ook per e-mail melden via:
medinfo@formycon.com
Verwerking van de gegevens gebeurt altijd in overeenstemming met de wettelijke vereisten. Meer informatie vindt u hier.
Legal Notice
Legal Notice
Formycon AG
The Biosimilar Experts
Responsible Provider
in accordance with § 5 of the German Telemedia Act (TMG):
Formycon AG
Fraunhoferstraße 15
82152 Planegg-Martinsried
Germany
T + 49 89 864667 100
F + 49 89 864667 110
info@formycon.com
www.formycon.com
Management Board:
Dr. Stefan Glombitza, Nicola Mikulcik, Dr. Andreas Seidl, Enno Spillner
Supervisory Board:
Wolfgang Essler (Chairman), Colin Bond (Deputy Chairman), Nicholas Haggar, Klaus Röhrig, Dr. Bodo Coldewey, Dr. Graham Dixon
Commercial register:
District Court of Munich HRB 200801
Register number:
HRB 200801
VAT number:
according to § 27 a sales tax law:
DE257092400
Responsible:
in accordance with § 55 Para. 2 of the German Interstate Treaty on Broadcasting (Rundfunkstaatsvertrag – RStV)
Enno Spillner
Privacy Policy
Privacy Policy
Privacy Policy of
Formycon AG
1. Contact details
The controller responsible for processing personal data on this website is:
Formycon AG (hereinafter referred to as “we”)
Fraunhoferstraße 15
82152 Planegg-Martinsried
T: +49 89 864667 100
info@formycon.com
You can contact our data protection officer at:
Formycon AG
Data Protection Officer
Fraunhoferstraße 15
82152 Planegg-Martinsried
datenschutz@formycon.com
2. General processes
When you visit our website, our system automatically collects data and information from the device you are using. This includes, among other things, the browser type, operating system, IP address, date and time of access, pages visited, the website you visited previously (referrer), and similar technical information. This data is processed for the purpose of delivering the website, ensuring system security and stability, and averting danger, for example in the event of a cyberattack. No personal evaluation takes place; the data is analyzed anonymously for statistical purposes. The legal basis for processing is our legitimate interest pursuant to Art. 6 (1) (f) GDPR in achieving the above-mentioned purposes.
The data is deleted after seven days at the latest; longer storage only takes place in anonymized form. Since the collection of this data is mandatory for the operation of the website, there is no possibility of objection.
3. Contact, reporting of side effects
3.1 Contact requests
On our website, you have the option of contacting us—for example, via a contact form, by email, or by phone. We process the data transmitted in this way exclusively for the purpose of processing your inquiry. The legal basis is our legitimate interest in responding to inquiries in accordance with Art. 6 (1) (f) GDPR. The data will be deleted as soon as it is no longer required for communication purposes, unless statutory retention obligations prevent deletion.
3.2 Reporting side effects of our medicines
We offer you the opportunity to report any side effects you experience with our medicines via our dedicated email address medinfo@formycon.com. We process the information you provide in the report in order to review the report, to ask you any questions we may have, and, if necessary, to forward it to the competent drug regulatory authority in pseudonymized form.
We are legally obliged to document and report side effects. In individual cases, it may be necessary to ask you questions about your side effects. If required by law, we enter the report in pseudonymized form into the designated (EudraVigilance) database of the authorities and into our own pharmacovigilance system (system for monitoring and analyzing side effects). We use the service provider Midas (Midas Pharma GmbH, Rheinstraße 49, 55218 Ingelheim, Germany). The data is stored in our system in order to fulfill our legal obligations in connection with the provision and risk monitoring of medicinal products and to analyze side effects in order to minimize the risks of their occurrence as far as possible.
Our legal basis for processing your data when reporting side effects and making inquiries is Art. 6 (1) (c) GDPR (compliance with a legal obligation) and Art. 9 (2) (i) GDPR (reasons of public interest in the area of public health).
We share information on side effects with recipients who may be involved in the processing, analysis, and consideration of side effects, such as private experts, quality assurance service providers, legal advisors, authorities, liability insurers, etc.
We store the information you provide on side effects in accordance with the legal obligation for as long as the product is available on the market and for 10 years thereafter.
3.3 Contact within the framework of existing customer relationships
Within the framework of ongoing customer relationships, we regularly contact our customers or their contact persons, for example to coordinate content, clarify open questions, make changes to the terms of the contract, or transmit relevant information. The processing of personal data is carried out for the purpose of performing the contractual relationship in accordance with Art. 6 (1) (b) GDPR or, where necessary, on the basis of our legitimate interest in efficient communication in accordance with Art. 6 (1) (f) GDPR.
4. Website functions
When you use our digital offerings, we process certain technical data to ensure the security, stability, and functionality of our systems. This includes, for example, troubleshooting, maintenance, IT security measures, or hosting our applications. This processing is based on our legitimate interest and, where relevant, on the fulfillment of legal obligations.
The technical log data is usually only stored for a short period of time and deleted or anonymized after 7 days at the latest, unless security-related tracking is required.
5. Web services used
We use various web services on our website to optimize the website and to present the information provided to you in the best possible way.
5.1 Matomo
On our website, we use the Matomo service from InnoCraft Ltd (7 Waterloo Quay, PO 625, 6140 Wellington, New Zealand) to analyze the use of our website and continuously improve our online offering.
Matomo works on our website without cookies and without accessing data from the user’s device. The analysis is carried out entirely on the server side. The following information is primarily processed: IP address (filtered/anonymized), device and browser characteristics, pages accessed, length of stay, and interactions.
The processing of personal data is based on Art. 6 (1) lit. f GDPR. Our legitimate interest lies in analyzing usage behavior in order to optimize our online offering. The data is stored for 13 months and then deleted or anonymized.
Processing takes place exclusively on servers in the EU or in secure third countries for which the Commission has issued an adequacy decision. No data is transferred to unsafe third countries. Further information can be found in Matomo’s privacy policy at https://matomo.org/privacy-policy/.
You have the option of preventing your actions on our website from being analyzed. You can object to processing at any time using the following option.
Your visit to this website is currently being tracked by Matomo web analytics. Deselect this checkbox to opt out / Your visit to this website is currently not being tracked by Matomo web analytics. Select this checkbox to opt in.
5.2 Cookies
Our website uses so-called cookies. These are small text files that can be stored and read by the browser used on the user’s device. Cookies can either be stored only for the duration of a session and then automatically deleted (session cookies) or remain permanently on the end device (persistent cookies).
Insofar as cookies are absolutely necessary for the technical operation and provision of our online offering, their use is based on Section 25 (2) No. 2 TDDDG. The associated processing of personal data is carried out in accordance with Art. 6 (1) lit. f GDPR in order to make our website functional, secure, and user-friendly.
Insofar as cookies are also used for analysis, statistical, or marketing purposes, this is done on the basis of your consent in accordance with § 25 (1) TDDDG. In these cases, the processing of personal data is based on Art. 6 para. 1 lit. a GDPR. Consent that has been given can be revoked at any time with effect for the future.
You can use the following button to view your current cookie settings, obtain detailed information about the cookies used, and manage your consent: [Cookie settings]
6. Recipients of the data
In order to fulfill our contractual and legal obligations and to perform our services, it may be necessary to disclose personal data to third parties. This applies in particular to authorities, parties involved in proceedings (e.g., opponents, affected parties, participants), banks, and insurance companies.
We also use external service providers to support our operational processes, to whom personal data may be transferred in the course of their activities. If these service providers process personal data on our behalf, this is done on the basis of a data processing agreement in accordance with Art. 28 GDPR. Processing takes place exclusively within the EU or the EEA or in compliance with appropriate safeguards within the meaning of Art. 44 ff. GDPR.
7. Rights of data subjects
You have the following rights:
- Right to information: You can request information from us about whether and which personal data we process about you (Art. 15 GDPR).
- Right to rectification: If data that we process about you is incorrect, you have the right to request that we correct this data (Art. 16 GDPR).
- Right to erasure / right to be forgotten: If personal data is no longer necessary for our processing purposes or if the legal basis no longer applies due to other circumstances, you have the right to have your personal data erased (Art. 17 GDPR).
- Right to restriction of processing: Under certain conditions, you can request that we restrict the processing of your data (Art. 18 GDPR).
- Right to data portability: You can request a copy of your data from us in a commonly used machine-readable format or request that we provide the data directly to a provider of your choice (Art. 20 GDPR).
- Right to object: You can object to the processing if it is based on our legitimate interests (Art. 21 GDPR).
- Automated decisions: You have the right not to be subject to an automated decision exclusively (Art. 22 GDPR).
- Right to complain to a supervisory authority: You have the right to complain to a data protection supervisory authority about the processing of your personal data if you do not agree with the handling of your data (Art. 77 GDPR).
To exercise your rights against us, you can contact our data protection officer at any time using the contact details provided above.
As of June 2025
